Glory Biotech and KainosMed announced on the 15th that they had signed a strategic alliance to jointly enter the African and Chinese markets.
The partnership aims to expand both companies' business areas and secure global growth engines by combining Glory Biotech's multi-year experience in entering the African market based on innovative technologies, KinosMed's AIDS treatment technology, and know-how in targeting the Chinese market.
Glory Biotech plans to expand its AIDS diagnosis and treatment business in the African market by utilizing KainosMed's AIDS treatment technology, and KainosMed plans to accelerate its entry into overseas markets based on Glory Biotech's experience in entering the African market.
The two companies expect the partnership to combine each other's strengths to create synergies and serve as a springboard to grow into a global leader in AIDS diagnosis and treatment.
Glory Biotech has a technology that tests the immune function of white blood cells in the blood by applying microfiltering patent technology with fine filters and special reagents in the existing method of separating white blood cells by centrifugation to increase the accuracy of the test in the existing blood immune cell test technology. The Korea Credit Guarantee Fund has already selected the first penguin business through this innovative technology.
The company explained that it has a unique technology that can quickly and accurately measure the number of AIDS antibodies called CD4 among immune cells present in white blood cells, and that the "ICA100" equipment, an AIDS monitoring device that applies this core technology, is highly mobile and can be operated by unskilled people at the clinic site where patients are located.
In particular, it is said to be well-received in underdeveloped countries in Africa due to its low price and high measurement accuracy. Currently, more than 100 units are installed in health clinic centers in South Africa, making it possible to accurately and easily check the number of immune cells within 10 minutes with a small amount of blood drawn directly from the site when conducting regular annual tests on 8 million local AIDS-infected patients.
Instead of expensive blood test equipment previously handled only by analysis equipment experts, anyone in health care can easily operate it and perform blood tests.
Glory Biotech is attracting attention in the AIDS patient monitoring market by being invited by the WHO AIDS Countermeasures Program for its innovation in technology and solutions, and is also looking forward to expanding the African market.
Meanwhile, Glory Biotech, a company that develops and sells immune cell testing equipment, achieved $1 million in exports in 2023 and successfully secured a bridgehead for exports to south-central Africa, including Kenya and Uganda. It is also anticipating sales growth as it will be able to continue supplying cartridges and reagents as test consumables along with equipment exports.
Kainosmed is a company that has developed AIDS treatment technology, gone through clinical trials, and succeeded in commercial products through China's Jangsu ID. It is preparing to enter the global market beyond the Chinese AIDS treatment market.
Glory Biotech and KainosMed announced on the 15th that they had signed a strategic alliance to jointly enter the African and Chinese markets.
The partnership aims to expand both companies' business areas and secure global growth engines by combining Glory Biotech's multi-year experience in entering the African market based on innovative technologies, KinosMed's AIDS treatment technology, and know-how in targeting the Chinese market.
Glory Biotech plans to expand its AIDS diagnosis and treatment business in the African market by utilizing KainosMed's AIDS treatment technology, and KainosMed plans to accelerate its entry into overseas markets based on Glory Biotech's experience in entering the African market.
The two companies expect the partnership to combine each other's strengths to create synergies and serve as a springboard to grow into a global leader in AIDS diagnosis and treatment.
Glory Biotech has a technology that tests the immune function of white blood cells in the blood by applying microfiltering patent technology with fine filters and special reagents in the existing method of separating white blood cells by centrifugation to increase the accuracy of the test in the existing blood immune cell test technology. The Korea Credit Guarantee Fund has already selected the first penguin business through this innovative technology.
The company explained that it has a unique technology that can quickly and accurately measure the number of AIDS antibodies called CD4 among immune cells present in white blood cells, and that the "ICA100" equipment, an AIDS monitoring device that applies this core technology, is highly mobile and can be operated by unskilled people at the clinic site where patients are located.
In particular, it is said to be well-received in underdeveloped countries in Africa due to its low price and high measurement accuracy. Currently, more than 100 units are installed in health clinic centers in South Africa, making it possible to accurately and easily check the number of immune cells within 10 minutes with a small amount of blood drawn directly from the site when conducting regular annual tests on 8 million local AIDS-infected patients.
Instead of expensive blood test equipment previously handled only by analysis equipment experts, anyone in health care can easily operate it and perform blood tests.
Glory Biotech is attracting attention in the AIDS patient monitoring market by being invited by the WHO AIDS Countermeasures Program for its innovation in technology and solutions, and is also looking forward to expanding the African market.
Meanwhile, Glory Biotech, a company that develops and sells immune cell testing equipment, achieved $1 million in exports in 2023 and successfully secured a bridgehead for exports to south-central Africa, including Kenya and Uganda. It is also anticipating sales growth as it will be able to continue supplying cartridges and reagents as test consumables along with equipment exports.
Kainosmed is a company that has developed AIDS treatment technology, gone through clinical trials, and succeeded in commercial products through China's Jangsu ID. It is preparing to enter the global market beyond the Chinese AIDS treatment market.